Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 9 | 2024 | 177 | 1.790 |
Why?
|
| Hyperthermia, Induced | 8 | 2024 | 73 | 1.690 |
Why?
|
| Appendiceal Neoplasms | 7 | 2023 | 27 | 1.490 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 37 | 1.280 |
Why?
|
| Colonic Neoplasms | 4 | 2024 | 556 | 1.140 |
Why?
|
| Colorectal Neoplasms | 8 | 2024 | 938 | 1.060 |
Why?
|
| Rectal Neoplasms | 3 | 2024 | 116 | 0.640 |
Why?
|
| Cytoreduction Surgical Procedures | 11 | 2024 | 73 | 0.590 |
Why?
|
| Adenocarcinoma | 4 | 2023 | 1169 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 2438 | 0.410 |
Why?
|
| Combined Modality Therapy | 7 | 2024 | 1686 | 0.290 |
Why?
|
| Survival Rate | 7 | 2023 | 1863 | 0.290 |
Why?
|
| Peritoneum | 4 | 2024 | 57 | 0.230 |
Why?
|
| Surgical Oncology | 1 | 2023 | 27 | 0.230 |
Why?
|
| Appendix | 1 | 2023 | 31 | 0.220 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 190 | 0.210 |
Why?
|
| Retrospective Studies | 10 | 2023 | 8489 | 0.210 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 52 | 0.200 |
Why?
|
| Palliative Care | 1 | 2023 | 257 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 64 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 1939 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2262 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2024 | 272 | 0.190 |
Why?
|
| Mitoxantrone | 1 | 2020 | 68 | 0.180 |
Why?
|
| Humans | 22 | 2024 | 86643 | 0.180 |
Why?
|
| Etoposide | 1 | 2020 | 196 | 0.180 |
Why?
|
| Cytarabine | 1 | 2020 | 218 | 0.180 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 1464 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 736 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 589 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1075 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1052 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 110 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 763 | 0.120 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 41 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1313 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 1204 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 2360 | 0.090 |
Why?
|
| Recurrence | 2 | 2023 | 1139 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2023 | 2767 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 2898 | 0.070 |
Why?
|
| Adult | 5 | 2023 | 25648 | 0.070 |
Why?
|
| Mutation | 3 | 2023 | 3968 | 0.070 |
Why?
|
| Middle Aged | 5 | 2023 | 25028 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 4213 | 0.060 |
Why?
|
| Male | 6 | 2023 | 40965 | 0.060 |
Why?
|
| Trifluridine | 1 | 2023 | 6 | 0.060 |
Why?
|
| Female | 6 | 2023 | 44532 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 43 | 0.060 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.060 |
Why?
|
| Organ Sparing Treatments | 1 | 2023 | 38 | 0.060 |
Why?
|
| Preoperative Period | 1 | 2023 | 91 | 0.060 |
Why?
|
| Leucovorin | 1 | 2023 | 218 | 0.060 |
Why?
|
| Anal Canal | 1 | 2023 | 89 | 0.050 |
Why?
|
| Monoterpenes | 1 | 2022 | 5 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 50 | 0.050 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2021 | 11 | 0.050 |
Why?
|
| Celecoxib | 1 | 2022 | 31 | 0.050 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 11 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 262 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 468 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2023 | 556 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 224 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 407 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 318 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 397 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 301 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 289 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 381 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2021 | 303 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2022 | 684 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 458 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2021 | 790 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 456 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1239 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 971 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1163 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 388 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1823 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1531 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 702 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 920 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1718 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2426 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1578 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1585 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 3679 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1683 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 462 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 18415 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 860 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 3241 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2207 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 7993 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 5976 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 11352 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 26582 | 0.010 |
Why?
|